Introduction {#s1}
============

Thyroid hormones (THs), triiodothyronine (T~3~) and thyroxine (T~4~), regulate some target genes transcriptions through TH receptors α (TRα) or β (TRβ) in cell nucleus (Cheng et al., [@B9]) or nongenomic actions in cytoplasm (Davis et al., [@B11]). Type 2 deiodinase enzyme is responsible for the conversion of T~4~ to nuclear active T~3~ (Baumgartner et al., [@B4]). THs play critical roles in the regulation of neurogenesis, neuronal proliferation and migration, dendritic branching and synaptogenesis, glial differentiation and migration, axonal outgrowth and myelination, brain maturation and cognitive functions (Williams, [@B49]; Raymaekers and Darras, [@B33]) and so on. Homeostatic equilibria of THs depend on dynamic inter-relationships among THs, pituitary thyrotropin and hypothalamic thyrotropin-releasing hormone (Hoermann et al., [@B18], [@B19]). THs dysfunctions are accompanied by some neurological (Raymaekers and Darras, [@B33]) and psychiatric disorders, as well as cognitive impairments such as abnormal working memory in some patients with Graves' disease (Jabłkowska et al., [@B20]) or subclinical hypothyroidism (Beydoun et al., [@B5]), the autobiographical memory deficits in patients with early TH deficiency (Willoughby et al., [@B50]). Animal study proves that both systemic levothyroxine (LT~4~) injection and hypothyroidism impaired spatial memory of rats in Y-maze (Taşkin et al., [@B44]; Artis et al., [@B3]). Neonatal rats treated with T~3~ showed impaired spatial memory and synaptic long-term potentiation (LTP) induction in hippocampus (Pavlides et al., [@B29]). However, intracerebroventricular administration of T~3~ before retrieval can improve passive avoidance memory in rat model of ischemic brain stroke (Mokhtari et al., [@B27]). Daily intraperitoneally injected with LT~4~ for 3 months restored impaired spatial memory in aged mice (Fu et al., [@B15]). Supplementation with T~3~ or T~4~ 2 weeks before training blocked the enhancement of fear memory in a hypothyroid mouse model (Buras et al., [@B8]). However, the role of THs in the different stages of memory, which will strengthen understanding the mechanisms underlying contribution of THs to memory disorders, is still poorly understood. In this study, we used systemic and hippocampal administration of LT~4~, which is widely used to treat hypothyroidism in clinic and can be converted into T~3~ in euthyroid rats, to explore the role of THs in the different stages of memory.

The hippocampus, a TH receptor-rich region (Singh et al., [@B40]), plays vital roles in memory processes. Several findings indicate that THs regulate hippocampus-dependent memory processes. In clinic, patients with hyperthyroid disorders show being decreased gray matter volumes in hippocampus (Zhang et al., [@B53]). Meanwhile, some patients with congenital hypothyroidism show abnormal hippocampal function and verbal memory (Wheeler et al., [@B47]). THs replacement treatment improves hippocampus-dependent learning and memory in hypothyroid animals (Ge et al., [@B16]) and humans (Miller et al., [@B26]). T~3~ administration in hippocampus enhances long-term memory for trace cued and delays contextual fear conditioning in rats (Sui et al., [@B41]).

Here, we aim to investigate the effects of LT~4~ administrated into hippocampus on the different stages of fear memory process.

Materials and Methods {#s2}
=====================

Animals {#s2-1}
-------

Male Sprague-Dawley rats (Animal House Center, Kunming Medical University, China), weighing 250--300 g, 11--12 weeks old, were used. Rats were individually housed in home cages with *ad libitum* access to water and food (complying with the Chinese rat food standard GB 14924.3-2001) and subjected to a 12-h light/12-h dark cycle (lights on at 7 am) in a temperature-regulated room. Rats were allowed 1 week to acclimate our research facility before manipulations. All experiments were performed between 09:00 and 12:00. This study was carried out in accordance with the recommendations of the National Institutes of Health on experimental animal care and use. All experimental protocols were approved by the Animal Ethics Committee of the Kunming Institute of Zoology, Chinese Academy of Sciences.

Cannula Implantation and Drug Infusion {#s2-2}
--------------------------------------

The protocol of cannula implantation was similar to our previous study (Zhou et al., [@B54]). Surgery was performed under the anesthesia of pentobarbital sodium salt (Sigma, USA, dissolved in saline, 60 mg/kg body weight, I.P.). Rats were ventilated with 95% O~2~/5% CO~2~ through a mask and mounted in a stereotaxic apparatus (RWD Life Science Co., Shenzhen, China). Small holes were bilaterally drilled in the skull for the placement of two stainless-steel guide cannulae (7 mm length, 26 gauges) in the dorsal hippocampus (DH). The cannula tips were targeted to 1 mm above the DH with the coordinate of anteroposterior = −3.8 mm from the bregma, mediolateral = ±2.8 mm, dorsoventral = −3.0 mm. Cannula were affixed to the skull using dental cement. A stylet was introduced into the guide cannula to prevent possible obstruction. The rats were allowed to recover for 7 days following surgery and handled for 3 days before behavioral experiments. To test the role of hippocampal THs in our behavioral paradigm, LT~4~ solution (Sigma, 0.4 μg/μl, saline as vehicle, 1 μl/side) was bilaterally injected into the hippocampus (I.H.) using a microsyringe pump at the speed of 0.2 μl/min with an injection pipe via cannula. After all behavioral tests, an injection pipe used in the experiments was inserted into the cannula for infusing 1 μl trypan blue as a marker to test the accuracy of cannula placement in each rat.

FT~4~, FT~3~ Levels in Serum or Brain Tissues {#s2-3}
---------------------------------------------

The rats were anesthetized using ether at all scheduled time points after intraperitoneal drug administration (I.P.), and their heart blood samples were obtained to test serum levels of free tetraiodothyroxine (FT~4~) and free triiodothyronine (FT~3~). For collecting brain tissues, rats were perfused from left ventricle with saline 500 ml for 30 min after anesthesia of pentobarbital sodium salt (Sigma, 60 mg/kg body weight). Immediately at the end of saline perfusion, dissection of their hippocampus and prefrontal cortices (PFC) were followed (Chiu et al., [@B10]). Sample of bilateral hippocampus or PFC was individually homogenized in artificial cerebral spinal fluid (ACSF; Mahmoud and Amer, [@B25]) by the ratio of 1 μg/4 μl (brain tissues/ACSF) in an ice surrounded homogenizer and centrifuged at 14,000 rpm for 15 min at 4°C. The resulting supernatant was collected and stored at −80°C until the determination of FT~4~ and FT~3~.

FT~4~ and FT~3~ were tested using time-resolved fluoroimmunoassays (TRFIA). Diagnostic kits for FT~4~ and FT~3~ (SYM Bio Lifescience Co., LTD, Suzhou, China) were used in conjunction with a multilabel counter (Wallac Vicotor 2 TM 1420 multilabel counter, Turku, Finland) to detect THs levels according to the manufacturer's instructions. The detection ranges for FT~4~ and FT~3~ were 0--74 pmol/L and 0--54 pmol/L, respectively. Whenever the concentration of a particular hormone exceeded the corresponding upper limit, the serum was further diluted with saline to achieve a measurable concentration. All tests were done in triplicate.

The Open Field Test {#s2-4}
-------------------

Locomotor activity and thigmotaxis of rats were tested in an open field at 24 H following LT~4~ or saline administration (I.P. or I.H., saline as vehicle). The rats were individually placed in the center of an open field (43 cm × 43 cm × 30 cm with virtual central zone in it, ENV-017M-027, Med Associates, Inc., St. Albans, VT, USA) and allowed to explore freely for 20 min. Rat movement was tracked using three 16-beam infrared arrays around the rat arena. The open field was cleaned with 5% ethanol after each test. The running distance reflected the locomotor activity and was automatically analyzed using the Med Associates software after test. Thigmotaxis was presented as the percentage (%) of the total distance moved (TDM) in the central zone of the test apparatus. Specifically, thigmotaxis was calculated as the ratio between TDM in the central zone and TDM over the whole test arena (including central and outer zones).

The Treadmill Test {#s2-5}
------------------

The protocol was similar to our previous study (Yu et al., [@B52]). The rats were placed onto a treadmill apparatus (Panlab Technology, Spain) following the same time window of LT~4~ or saline administration as that in the open field tests. The running intensity was set at 25 m/min with no incline. During a 5 min test, the running distance, which reflected fatigue resistance ability, was automatically recorded.

Histology {#s2-6}
---------

At completion of behavioral testing, the rats were administered (I.P.) an overdose of pentobarbital sodium (Sigma), infused 1 μl trypan blue into bilateral hippocampus through the guide cannula with the same injection needle tip depth as LT~4~ or saline infusion, and perfused transcardially with saline followed by 4% formaldehyde solution (in 0.1 M phosphate buffer). After extraction from the skull, the brains were removed and cryoprotected in 20% glycerol/10% formaldehyde solution for 3 days. Coronal sections (50 μm thickness) were cut through hippocampus with a freezing microtome (VT1000 S, Leica Biosystems, Germany), and wet-mounted on glass microscope slides with 70% ethanol. The nature and extent of the hippocampal lesion was verified by visual inspection of the stained brain sections. All rats had complete, bilateral lesions of the DH with sparing of axonal fibers of passage. All hippocampal lesions in this experiment were virtually identical.

Contextual Fear Conditioning {#s2-7}
----------------------------

The protocol was similar to that in our previous studies (Zhou et al., [@B54]). During the training process, rats were placed in a chamber (32 × 25 × 25 cm; Med Associates Inc., St. Albans, VT, USA), allowed to freely explore the box for 2 min, and then received 5-trial foot shocks (0.8 mA, 2 s) with 2-min intervals. The freezing time, which reflected the expression of the fear response to the context or aversive stimulus, was automatically recorded by software (Video Freeze V2.5.5.0, Med Associates, Inc., St. Albans, VT, USA) before the first conditioning trial (Pre), and the freezing times were again measured during the 2-min interval after each conditioning trial to reflect the level of acquisition. To test contextual memory, the rats were placed back in the box for 5 min without foot shocks on day 1 (test 1), day 7 (test 2), and day 14 (test 3) post training. The freezing time was recorded to represent the level of memory. All experimenters were blinded to the group assignment of the animals.

To test the systemic effects of THs on fear memory, rats were injected (I.P.) with LT~4~ (Sigma, 15 μg/ml × 1 ml/kg body weight) immediately after fear conditioning. To test the contributions of THs in hippocampus to fear memory, rats were directly injected with LT~4~ into DH 1 day before, immediately, 2 h or 23.5 h after fear conditioning. All control rats were injected saline (1 ml/kg body weight during systemic LT~4~ administration or 1 μl/side hippocampus during hippocampal LT~4~ administration) with the same injection sites as experimental rats.

Statistical Analysis {#s2-8}
--------------------

The percent time freezing (total freezing time/120 s × 100%) every 120 s in six consecutive observations during fear conditioning or (total freezing time/300 s × 100%) during the fear memory test for 300 s for each rat was calculated. All data were represented as mean ± SEM. Independent *Student*'s *t*-test, repeated measures ANOVA, and one-way ANOVA followed by *post hoc* Bonferroni's test were used for statistical analyses according to experimental designs (SPSS 16.0 version). *P* \< 0.05 was considered to be statistically significant.

Results {#s3}
=======

The Effects of a Single Systemic Injection of LT~4~ on THs in Serum and Hippocampus, and Contextual Fear Memory {#s3-1}
---------------------------------------------------------------------------------------------------------------

To examine the effects of systemic injection of LT~4~ on the level of free THs in serum and hippocampus, rats were received a single LT~4~ administration (15 μg/kg, I.P.). The data with one-way ANOVA analysis showed that the serum FT~4~ and FT~3~ was significantly increased from 2 h to 3 days and returned to baseline 7 days after administration (Figure [1A](#F1){ref-type="fig"}, FT~4~: *F*~(4,15)~ = 163.26, *P* \< 0.001; *post hoc*: 2 h, *P* \< 0.001; 1 day, *P* \< 0.001; 3 days, *P* \< 0.001; 7 days, *P* \> 0.99, respectively, compared with control group. FT~3~: *F*~(4,15)~ = 39.81, *P* \< 0.001; *post hoc*: 2 h, *P* \< 0.001; 1 day, *P* \< 0.001; 3 days, *P* \< 0.05; 7 days, *P* \> 0.99, respectively, compared with control group; *n* = 4 in each time point). Meanwhile, the hippocampal FT~4~ and FT~3~ was also increased from 2 h to 1 day after LT~4~ administration in one-way ANOVA analysis (Figure [1B](#F1){ref-type="fig"}, FT~4~: *F*~(4,15)~ = 7.47, *P* = 0.005; *post hoc*: 2 h, *P* \< 0.01; 1 day, *P* = 0.04; 3 days, *P* = 0.36; 7 days, *P* \> 0.99, respectively, compared with control group. FT~3~: *F*~(4,15)~ = 6.21, *P* = 0.009; *post hoc*: 2 h, *P* \> 0.99; 1 day, *P* = 0.019; 3 days, *P* \> 0.99; 7 days, *P* \> 0.99, respectively, compared with control group).

![Effects of systemic injection of LT~4~ on thyroid hormones (THs) in serum and hippocampus. The time course of THs concentration after a single systemic administration of LT~4~ (15 μg/kg, I.P.) in **(A)** serum and **(B)** hippocampus. **(C)** Left: rats were intraperitoneally injected with LT~4~ immediately after fear conditioning and carried out dependent 1-day, 7-day, 14-day memory tests; Middle: the learning curve during fear conditioning training; Right: contextual fear memory tests 1 day, 7 days and 14 days after training. LT~4~ group, rats injected with LT~4~; Control group, rats injected with saline. Numbers in bars represent animal numbers. I.P., intraperitoneal injection; H, hour; D, day; LT~4~, levothyroxine; FT~4~, free tetraiodothyronine; FT~3~, free triiodothyronine. \**P* \< 0.05, ^&^*P* \< 0.01, ^\#^*P* \< 0.001.](fncel-11-00223-g0001){#F1}

To examine the effects of systemic injection of LT~4~ on fear memory formation, rats were injected with LT~4~ (15 μg/kg, I.P.) immediately after fear conditioning (Figure [1C](#F1){ref-type="fig"}, left). There was no significant difference in the fear memory acquisition between control group and LT~4~-injection group represented by the learning curve (Figure [1C](#F1){ref-type="fig"}, middle: repeated measures ANOVA, *F*~(1,14)~ = 0.18, *P* = 0.67), which indicated that the acquisition of fear conditioning between two groups was similar to each other. However, during the following dependent fear memory tests, the rats injected with LT~4~ showed the decreased freezing level compared to control group (Figure [1C](#F1){ref-type="fig"}, right: repeated measures ANOVA, *F*~(1,14)~ = 14.09, *P* = 0.002; *post hoc*: 1 day, *P* = 0.009; 7 days, *P* \< 0.001; 14 days, *P* \< 0.001, respectively, compared with control group), which indicated that LT~4~ administration (I.P.) immediately after fear conditioning prevented the maintenance of long-term memory.

Thus, systemic administration (I.P.) of LT~4~ increased the FT~4~ and FT~3~ levels in serum and hippocampus, and impaired long-term fear memory maintenance.

The Effects of Hippocampal Administration of LT~4~ on FT~4~ and FT~3~ in Hippocampus, Prefrontal Cortex and Serum and on Locomotor Activity and Thigmotaxis {#s3-2}
-----------------------------------------------------------------------------------------------------------------------------------------------------------

As systemic injection of LT~4~ induced dramatical changes of THs in hippocampus, we hypothesized that the hippocampal THs have critical roles on some processes. To address this question, rats were directly injected with LT~4~ into DH. All of our experimental rats for drugs administration in hippocampus were histologically verified the identical loci of injection needle tips in DH and the patency of all tracts for drugs infusion, which was represented by a trypan blue-stained coronal brain from a rat having ever been injected LT~4~ into the DH (Figure [2A](#F2){ref-type="fig"}; Bradley et al., [@B7]). The results showed that only FT~4~ but not FT~3~ was increased in hippocampus after LT~4~ injection (Figure [2B](#F2){ref-type="fig"}, FT~4~: one-way ANOVA, *F*~(4,15)~ = 113.79, *P* \< 0.001; *post hoc*: 4 h, *P* \< 0.001; 1 day, *P* = 0.007; 3 days, *P* \< 0.05; 7 days, *P* \> 0.99, respectively, compared with control group. FT~3~: one-way ANOVA, *F*~(4,15)~ = 1.41, *P* = 0.28), in which the contribution of the local conversion of FT~4~ to FT~3~ was similar to the previous study (van Doorn et al., [@B46]). The increased concentration of FT~4~ in hippocampus post LT~4~ injection lasted at least 3 days and recovered to normal level 7 days later. Meanwhile, a single intrahippocampal LT~4~ injection did not change the level of THs in PFC (Figure [2C](#F2){ref-type="fig"}, FT~4~: control group vs. LT~4~ group, *t* = 0.03, *P* = 0.97; FT~3~: control group vs. LT~4~ group, *t* = 0.33, *P* = 0.75), which was similar to the previous document (van Doorn et al., [@B45]). After the above LT~4~ injection, FT~4~ and FT~3~ in serum also did not increase (Figure [2D](#F2){ref-type="fig"}, FT~4~: control group vs. LT~4~ group, *t* = 0.86, *P* = 0.42; FT~3~: control group vs. LT~4~ group, *t* = 0.09, *P* = 0.92).

![Effects of intrahippocampal injection of LT~4~ on free THs in hippocampus, prefrontal cortex (PFC) and serum, locomotor activity and thigmotaxis. **(A)** The position of the trypan blue-stained area was the histological demonstration of cannula tracts and the typical location for delivery of LT~4~ to hippocampus. **(B)** The time course of hippocampal THs concentration after hippocampal injection of LT~4~ (0.4 μg/μl, 1 μl/side). **(C)** The THs concentration in PFC 1 day after hippocampal injection of LT~4~. **(D)** The THs concentration in serum 4 h after hippocampal injection of LT~4~. **(E)** The open field test 1 day after hippocampal injection of LT~4~. **(F)** The treadmill test 1 day after hippocampal injection of LT~4~. **(G)** The thigmotaxis 1 day after hippocampal injection of LT~4~. Numbers in bars represent animal numbers. I.H., intrahippocampus; PFC, prefrontal cortex; H, hour; D, day; LT~4~, levothyroxine; FT~4~, free tetraiodothyronine; FT~3~, free triiodothyronine. \**P* \< 0.05, ^&^*P* \< 0.01, ^\#^*P* \< 0.001.](fncel-11-00223-g0002){#F2}

In addition, intra-hippocampal injection of LT~4~ did not affect the locomotor activity represented by the total distance in open field test (Figure [2E](#F2){ref-type="fig"}, control group vs. LT~4~ group, *t* = 0.42, *P* = 0.67), the fatigue resistance ability represented by the total distance in treadmill test (Figure [2F](#F2){ref-type="fig"}, control group vs. LT~4~ group, *t* = 0.86, *P* = 0.40), and the thigmotaxis represented by the percentage of the TDM in the central zone of the test apparatus (Figure [2G](#F2){ref-type="fig"}, control group vs. LT~4~ group, *t* = −0.806, *P* = 0.44) which was similar to the previous document (Wilcoxon et al., [@B48]).

Taken together, LT~4~ infusion in hippocampus selectively increased hippocampal FT~4~ but not FT~3~ concentration in rats. The high level of hippocampal FT~4~ did not change the locomotor activity, the fatigue resistance ability and thigmotaxis.

The Effects of Hippocampal Administration of LT~4~ on the Stages of Contextual Fear Memory Process {#s3-3}
--------------------------------------------------------------------------------------------------

To test the effects of high level of hippocampal THs on contextual fear memory acquisition, rats were directly injected with LT~4~ into DH through the cannula 1 day before fear conditioning and then carried out dependent memory tests on the day 1, day 7 and day 14 post fear conditioning (Figure [3A](#F3){ref-type="fig"}, left). The results indicated that the high level of hippocampal THs did not impair the fear memory acquisition represented by the learning curve during the conditioning (Figure [3A](#F3){ref-type="fig"}, middle. Repeated measures ANOVA, *F*~(1,19)~ = 0.47, *P* = 0.49). However, a single LT~4~ injection impaired the contextual fear memory maintenance because the rats injected with LT~4~ in bilateral hippocampus showed the decreased tendency of freezing level during dependent tests (Figure [3A](#F3){ref-type="fig"}, right. Repeated measures ANOVA, *F*~(1,19)~ = 3.40, *P* = 0.08; *post hoc*: 1 day, *P* = 0.34; 7 days, *P* = 0.19; 14 days, *P* = 0.012, respectively, compared with control group). This data suggested that the abnormal high level of hippocampal THs might impair contextual fear memory consolidation.

![Effects of hippocampal injection of LT~4~ on contextual fear memory. **(A)** Left: hippocampal injection of LT~4~ 1 day before fear conditioning training; Middle: the learning curve during fear conditioning training; Right: contextual fear memory tests 1 day, 7 days and 14 days after training. **(B)** Left: hippocampal injection of LT~4~ immediately after fear conditioning; Middle: the learning curve during fear conditioning training; Right: contextual fear memory tests. **(C)** Left: hippocampal injection of LT~4~ 2 h after fear conditioning; Middle: the learning curve during fear conditioning training; Right: contextual fear memory tests. **(D)** Left: hippocampal injection of LT~4~ 30 min before contextual fear memory test; Middle: the learning curve during fear conditioning training; Right: contextual fear memory tests. LT~4~, levothyroxine; H, hour; D, day. \**P* \< 0.05, ^\#^*P* \< 0.001.](fncel-11-00223-g0003){#F3}

To confirm this hypothesis, rats were injected with LT~4~ into hippocampus immediately (Figure [3B](#F3){ref-type="fig"}, left) or 2 h (Figure [3C](#F3){ref-type="fig"}, left) after conditioning. The data showed that rats injected with LT~4~ in hippocampus indeed revealed being decreased freezing time during the dependent contextual fear memory tests using repeated measures ANOVA (Figure [3B](#F3){ref-type="fig"}, right; *F*~(1,26)~ = 17.46, *P* \< 0.001; *post hoc*: 1 day, *P* \< 0.001; 7 days, *P* = 0.026; 14 days, *P* \< 0.001, respectively, compared with control group; Figure [3C](#F3){ref-type="fig"}, right; *F*~(1,16)~ = 3.49, *P* = 0.049; *post hoc*: 1 day, *P* = 0.014; 7 days, *P* = 0.047; 14 days, *P* = 0.016, respectively, compared with control group), although all of these rats had similar fear learning ability represented by the learning curve using repeated measures ANOVA (Figure [3B](#F3){ref-type="fig"}, middle; *F*~(1,26)~ = 0.87, *P* = 0.35; Figure [3C](#F3){ref-type="fig"}, middle; *F*~(1,16)~ \< 0.001, *P* = 0.98).

Finally, to further exclude that this result was due to that the abnormal high level of hippocampal THs impaired fear memory retrieval, we extended the intrahippocampal injection time of LT~4~ to 23.5 h after fear conditioning, so that the changes of 1-D memory test should be used to reflect the roles of LT~4~ injection on memory retrieval (Figure [3D](#F3){ref-type="fig"}, left). The data suggested that rats injected with LT~4~ in hippocampus showed similar level of learning curve in repeated measures ANOVA (Figure [3D](#F3){ref-type="fig"}, middle; *F*~(1,18)~ = 0.38, *P* = 0.54) and dependent memory tests whatever the time post conditioning (Figure [3D](#F3){ref-type="fig"}, right; *F*~(1,\ 18)~ = 2.26, *P* = 0.15; *post hoc*: 1 day, *P* = 0.94; 7 days, *P* = 0.56; 14 days, *P* = 0.07, respectively, compared with control group). Thus, the high level of hippocampal THs did not impair the contextual fear memory retrieval.

Taken together, the hippocampal LT~4~ injection selectively impaired contextual fear memory consolidation, but not acquisition and retrieval.

Discussion {#s4}
==========

In the present study, we found that administration of LT~4~ in hippocampus immediately or 2 h after training impaired the long-term memory of fear conditioning, but pretest or posttraining administration did not affect the acquisition or retrieval. These findings demonstrate that the consolidation of fear memory rather than acquisition or retrieval was affected by hippocampal LT~4~ administration, which suggests that THs receptors or THs in hippocampus may be the modulator of fear memory. Montero-Pedrazuela et al. ([@B28]) have found that fear acquisition was not impaired, fear memory was enhanced, memory extinction was delayed, and spontaneous recovery of fear memory was exacerbated in adult-thyroidectomized Wistar rats. Contextual fear memory was enhanced in a hypothyroid mouse model, and supplementation with T~3~ or T~4~ 2 weeks before training blocked the enhancement of fear memory (Buras et al., [@B8]). Consistent with these results, we showed that a single systemic or hippocampal administration of LT~4~ impaired fear memory through memory consolidation impairment, which demonstrated for the first time that increased THs in hippocampus can impair fear memory. However, rats were administered T~3~ into the dorsal hippocampal before and after training both exhibited significantly increased long-term memory in contextual fear conditioning (Sui et al., [@B41]), which may result from the difference of drug administration and fear conditioning protocol.

In clinic, many patients with abnormal THs related diseases such as hypothyroidism and hyperthyroidism, are accompanied by memory impairments (Jabłkowska et al., [@B20]; Taşkin et al., [@B44]; de-Miranda et al., [@B12]; Shrestha et al., [@B39]). However, the improvements of impaired cognitive functions in patients are often ignored, as many patients still show cognitive disorders even after the THs returns to normal (Sui et al., [@B41]; Samuels, [@B36]; Jaracz et al., [@B21]), which indicates that the abnormal THs level could trigger long-term effects on cognitive functions. These may be due to that THs can regulate synaptic plasticity or molecules identified as mediators for memory processing (Raymaekers and Darras, [@B33]), including adult neurogenesis (Kapoor et al., [@B23], [@B24]), brain-derived neurotropic factor (BDNF; Yu et al., [@B52]), glutamic acid decarboxylase 65 (GAD65), neuron-specific K^+^/Cl^−^ co-transporter (KCC2; Sawano et al., [@B37]). THs can regulate the balance between synaptic LTP and long-term depression (LTD), which play an important role in memory process (Johansen et al., [@B22]). Most studies have addressed the effects of THs on synaptic plasticity following long-lasting treatments. Impaired LTP has been reported in LT~4~ treated rats (Pavlides et al., [@B29]; Taşkin et al., [@B44]) or hypothyroidism rats (Alzoubi et al., [@B2]; Artis et al., [@B3]). Hypothyroidism facilitates LTD (Alzoubi et al., [@B1]) while adult-onset hyperthyroidism causes a durable LTD in perforant pathway-dentate gyrus synapses in rats (Tan et al., [@B43]). One study has reported that acute intra-hippocampal infusion of LT~4~ can promote LTD over LTP via the integrin αvβ3 receptor (Bitiktas et al., [@B6]). The effects of THs on the synaptic plasticity and neuronal function maybe the mechanisms underlying the effect of hippocampal administration of LT~4~ on fear memory process.

Limbic regions including hippocampus and amygdala are involved in the circuitry of contextual fear conditioning (Phillips and LeDoux, [@B31]; Fang et al., [@B14]; Hegde et al., [@B17]) and sensitive to hormonal alterations. THs receptors are rich in both hippocampus and amygdala (Puymirat et al., [@B32]; Desouza et al., [@B13]; Singh et al., [@B40]). Stressors induced significant increase in the activity of type 2 deiodinase, which catalyzes T~4~ to the active T~3~ (Baumgartner et al., [@B4]). Montero-Pedrazuela et al. ([@B28]) reported that abnormal glucocorticoid signaling in the amygdala is an important pathophysiological mechanism underlying fear memory disorder in hypothyroidism. Hippocampus is only involved in fear conditioning situations involving complex, polymodal events, and plays a sensory relay role in fear conditioning. The critical roles of hippocampus in the processes of learning and memory have been generally accepted in human and animal studies (Winocur et al., [@B51]; Shin and Jadhav, [@B38]). THs in hippocampus may regulate memory processes through the regulated genes encoding many proteins involved in intracellular signaling pathways. This hypothesis has been partially proved by some previous studies. Hypothyroidism in early postnatal rats triggers a decrease in spatial memory by decreasing hippocampal synaptic plasticity (Salazar et al., [@B35]). Rats treated with T~3~ showed impaired spatial memory and synaptic LTP induction in hippocampus (Pavlides et al., [@B29]). LT~4~ daily intraperitoneally injected for 3 months restored impaired spatial memory in aged mice (Fu et al., [@B15]). However, the effects of hippocampal LT~4~ administration on the different stages of contextual fear memory are unknown.

In this study, single systemic administration of LT~4~ in rats rapidly increased the level of FT~4~ and FT~3~ in serum, which maintained at least for 3 days and returned to normal state post 7 days, which was similar to our previous study (Yu et al., [@B52]). Interestingly, along with increased level of serum LT~4~, the concentration of FT~4~ and FT~3~ in hippocampus were also increased, which suggested that THs may produce effects on hippocampus related functions such as hippocampus dependent memory. Furthermore, a single systemic LT~4~ administration after fear conditioning dramatically impaired fear memory even when the FT~3~ and FT~4~ returned to normal state (7 and 14 days after LT~4~ administration), which indicates the important role of hippocampal THs in fear memory process.

The roles of hippocampal THs on the stages of contextual fear memory were investigated by hippocampal injection of LT~4~. Our results showed after hippocampal injection of LT~4~, the level of FT~4~ but not FT~3~ increased in the hippocampus (van Doorn et al., [@B45]). Furthermore, the level of THs in PFC and serum did not changed, which was beneficial to focus studying on the influence of FT~4~ in hippocampus on fear memory. Compared with control group, rats received hippocampal LT~4~ injection 1 day before training showed contact learning and long-term memory detected on 1-day and 7-days, which demonstrated that the increased level of hippocampal THs did not affect contextual fear memory acquisition. However, the impaired 14-days long-term memory indicated the maintenance of long-term memory was influenced in hippocampal LT~4~ injection group. To address the role of hippocampal LT~4~ injection on the fear memory consolidation process, rats were injected with LT~4~ into hippocampus immediately or 2 h after conditioning, and these rats showed sustained long-term memory impairments from 1 day to 14 days. It was consistent with the results in systemic administration of LT~4~ immediately after fear conditioning. In contrast, hippocampal LT~4~ injection 30 min before 1-day test had no effect on the long-term memory, which demonstrated that the increased level of hippocampal THs did not affect fear memory retrieval. Thus, hippocampal administration of THs selectively prevented the consolidation of contextual fear memory. Furthermore, hippocampal LT~4~ injection did not change the locomotor activity and thigmotaxis in open field, and THs in serum or PFC, which might exclude the effect of other factors on memory. Further investigations studying the roles of THs on memory processes in different brain regions will be useful for understanding the mechanisms underlying the cognitive impairments induced by abnormal THs level.

Conclusion {#s5}
==========

In summary, our findings suggest that hippocampal administration of LT~4~ selectively impairs the consolidation of contextual fear memory in rats. THs modulation of aversive memories in hippocampus could be involved in etiology of emotional symptoms in THs dysfunction patients. The detailed understanding the role of THs in memory processes will provide mechanisms underlying contribution of THs to memory disorders.
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